The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Open accessAbstract
Inhibition of PCSK9 function is associated with an increase in pathogen lipid clearance, a decrease in the innate immune inflammatory response, and an improvement in septic shock clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
The Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Nadkarni, M. A., Martin, F. E., Jacques, N. A., & Hunter, N. (2002) · Microbiology · doi:10.1099/00221287-148-1-257 · Cited by 1,938
Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock
Russell, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hébert, P. C., Cooper, D. J., Holmes, C. L., Mehta, S., Granton, J. T., Storms, M. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa067373 · Cited by 1,924
Self-citationMyocardial Infarction Genetics Consortium (2009) · Nature Genetics · doi:10.1038/ng.327 · Cited by 1,088
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 1×
“After confirming by fluorescence-activated cell sorting analysis that the decline in LDLR expression reached a nadir by PCSK9 protein (3 mg/ml) (doses, 0, 1, 3, and 10 mg/ml) (26), we found that this dose resulted in a 65 ± 7.”
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Mechanisms of disease: genetic causes of familial hypercholesterolemia
Soutar, A. K., & Naoumova, R. P. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0836 · Cited by 608
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · cited 4×
“In humans, PCSK9 LOF genetic variants are associated with increased LDL clearance, whereasGOFmutations have the opposite effect (12, 14, 15, 19, 21).”
BackgroundInfluentialRegulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J., & Brown, M. S. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1194 · Cited by 421
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., et al. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1235 · Cited by 409
BOYD, J., MATHUR, S., WANG, Y., BATEMAN, R., & WALLEY, K. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.011 · Cited by 372
Self-citationBalance of inflammatory cytokines related to severity and mortality of murine sepsis
Walley, K. R., Lukacs, N. W., Standiford, T. J., Strieter, R. M., & Kunkel, S. L. (1996) · Infection and Immunity · doi:10.1128/iai.64.11.4733-4738.1996 · Cited by 366
Self-citationLi, H., Dong, B., Park, S. W., Lee, H.-S., Chen, W., & Liu, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052407 · Cited by 348
Boyd, J. H., Kan, B., Roberts, H., Wang, Y., & Walley, K. R. (2008) · Circulation Research · doi:10.1161/circresaha.107.167544 · Cited by 292
Self-citationBerberine decreases PCSK9 expression in HepG2 cells
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.004 · Cited by 233
Gene-centric Association Signals for Lipids and Apolipoproteins Identified via the HumanCVD BeadChip
Talmud, P. J., Drenos, F., Shah, S., Shah, T., Palmen, J., Verzilli, C., Gaunt, T. R., Pallas, J., Lovering, R., Li, K., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.10.014 · Cited by 191
A PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
Kathiresan, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707445 · Cited by 183
Neutralization and Transfer of Lipopolysaccharide by Phospholipid Transfer Protein
Hailman, E., Albers, J. J., Wolfbauer, G., Tu, A.-Y., & Wright, S. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12172 · Cited by 181
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
McNutt, M., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., & Lagace, T. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808802200 · Cited by 171
Flegel, W. A., Baumstark, M. W., Weinstock, C., Berg, A., & Northoff, H. (1993) · Infection and Immunity · doi:10.1128/iai.61.12.5140-5146.1993 · Cited by 169
Chen, S. N., Ballantyne, C. M., Gotto, A. M., Tan, Y., Willerson, J. T., & Marian, A. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.051 · Cited by 162
Levels, J. H. M., Marquart, J. A., Abraham, P. R., van den Ende, A., Molhuizen, H. O. F., van Deventer, S. J. H., & Meijers, J. C. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.4.2321-2326.2005 · Cited by 161
Candidate Gene Association Resource (CARe): Design, Methods, and Proof of Concept
Musunuru, K., Lettre, G., Young, T., Farlow, D., Pirruccello, J. P., Ejebe, K. G., Keating, B. J., Yang, Q., Chen, M., Lapchyk, N., et al. (2010) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.882696 · Cited by 152
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Steinberg, D. H., & Witztum, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904560106 · Cited by 111
Distribution and Kinetics of Lipoprotein-Bound Lipoteichoic Acid
Levels, J. H. M., Abraham, P. R., van Barreveld, E. P., Meijers, J. C. M., & van Deventer, S. J. H. (2003) · Infection and Immunity · doi:10.1128/iai.71.6.3280-3284.2003 · Cited by 111
Race and gender variation in response to evoked inflammation
Ferguson, J. F., Patel, P. N., Shah, R. Y., Mulvey, C. K., Gadi, R., Nijjar, P. S., Usman, H. M., Mehta, N. N., Shah, R. D., Master, S. R., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-63 · Cited by 109
Self-citationZhang, L., McCabe, T. J. D., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H. A., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 108
Scartezini, M., Hubbart, C., Whittall, R., Cooper, J. A., Neil, A., & Humphries, S. E. (2007) · Clinical Science · doi:10.1042/cs20070150 · Cited by 106
Crosstalk between reverse cholesterol transport and innate immunity
Azzam, K. M., & Fessler, M. B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.02.001 · Cited by 96
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial
Novack, V., MacFadyen, J. G., Malhotra, A., Almog, Y., Glynn, R. J., & Ridker, P. M. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111017 · Cited by 89
Gallay, P. A., Heumann, D., Roy, D. L., Barras, C., & Glauser, M. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.7922 · Cited by 88
Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation
Xiao, H., Sun, Z., Zhang, H.-B., & Zhang, D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70883-6 · Cited by 87
Gautier, T., & Lagrost, L. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390984 · Cited by 84
Scott, M. J., Liu, S., Shapiro, R. A., Yoram Vodovotz, B., & Billiar, T. R. (2009) · Hepatology · doi:10.1002/hep.22839 · Cited by 83
Genetic variants in PCSK9 affect the cholesterol level in Japanese
Shioji, K., Mannami, T., Kokubo, Y., Inamoto, N., Takagi, S., Goto, Y., Nonogi, H., & Iwai, N. (2004) · Journal of Human Genetics · doi:10.1007/s10038-003-0114-3 · Cited by 81
Effect of Plasma Phospholipid Transfer Protein Deficiency on Lethal Endotoxemia in Mice
Gautier, T., Klein, A., Deckert, V., Desrumaux, C. M., Ogier, N., Sberna, A.-L., Paul, C., Guern, N. L., Athias, A., Montange, T., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802802200 · Cited by 69
Mayne, J., Ooi, T. C., Raymond, A., Cousins, M., Bernier, L., Dewpura, T., Sirois, F., Mbikay, M., Davignon, J., & Chrétien, M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-70 · Cited by 63
The Meta-Genome of Sepsis: Host Genetics, Pathogens and the Acute Immune Response
Boyd, J. H., Russell, J. A., & Fjell, C. D. (2014) · Journal of Innate Immunity · doi:10.1159/000358835 · Cited by 59
Self-citationAssociation Between Statins Given in Hospital and Mortality in Pneumonia Patients
Rothberg, M. B., Bigelow, C., Pekow, P. S., & Lindenauer, P. K. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1826-2 · Cited by 46
Trinel, P. A., Plancke, Y. D., Gerold, P., Jouault, T., Delplace, F., Schwarz, R. Τ., Strecker, G., & Poulain, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30520 · Cited by 45
PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment
Tveten, K., Str⊘m, T. B., Berge, K. E., & Leren, T. P. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m034371 · Cited by 39
A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function
Gao, F., Ihn, H. E., Medina, M. W., & Krauss, R. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds559 · Cited by 36
Pocathikorn, A., Taylor, R. R., & Mamotte, C. D. S. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05337.x · Cited by 32
Antibodies against PCSK9—a new era of therapy
King, A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.166 · Cited by 13
The Potential for PCR Based Testing to Improve Diagnosis and Treatment of Sepsis
Lyle, N. H., & Boyd, J. H. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0350-4 · Cited by 10
Self-citation
Cited by
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“Several studies demonstrated that PCSK9 deficiency significantly reduced the levels of plasma pro-inflammatory cytokines IL-6, IL-8, TNF-α, and MCP-1.”
BackgroundSepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Tang, Z.-H., Peng, J., Ren, Z., Yang, J., Li, T.-T., Li, T.-H., Wang, Z., Wei, D.-H., Liu, L.-S., Zheng, X.-L., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.023 · Cited by 291
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Metadata
- Authors
- Walley, K. R., Thain, K. R., Russell, J. A., Reilly, M. P., Meyer, N. J., Ferguson, J. F., Christie, J. D., Nakada, T.-A., Fjell, C. D., Thair, S. A., Cirstea, M. S., & Boyd, J. H.
- Venue
- Science Translational Medicine
- Published
- 2014-10-15
- Volume
- 6
- Issue
- 258
- Pages
- 258ra143-258ra143
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W1990237691
- Cited by
- 355
- References
- 51
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.